Literature DB >> 16790705

Cyclophosphamide for scleroderma lung disease.

Fernando J Martinez, W Joseph McCune.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16790705     DOI： 10.1056/NEJMe068095

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

Review 1.  Evidence-based management of rapidly progressing systemic sclerosis.

Authors:  Dinesh Khanna; Christopher P Denton
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-06       Impact factor: 4.098

Review 2.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

Review 3.  [Therapy of systemic sclerosis].

Authors:  M Meurer; P Rehberger
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

4.  Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.

Authors:  Dinesh Khanna; James R Seibold; Athol Wells; Oliver Distler; Yannick Allanore; Chris Denton; Daniel E Furst
Journal:  Curr Rheumatol Rev       Date:  2010-05-01

5.  Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.

Authors:  Jonathan G Goldin; Grace Hyun J Kim; Chi-Hong Tseng; Elizabeth Volkmann; Daniel Furst; Philip Clements; Matt Brown; Michael Roth; Dinesh Khanna; Donald P Tashkin
Journal:  Ann Am Thorac Soc       Date:  2018-11

6.  Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide.

Authors:  Hyun J Kim; Matthew S Brown; Robert Elashoff; Gang Li; David W Gjertson; David A Lynch; Diane C Strollo; Eric Kleerup; Daniel Chong; Sumit K Shah; Shama Ahmad; Fereidoun Abtin; Donald P Tashkin; Jonathan G Goldin
Journal:  Eur Radiol       Date:  2011-09-17       Impact factor: 5.315

Review 7.  Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD).

Authors:  Adelle S Jee; Tamera J Corte
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

8.  Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

Authors:  Donald P Tashkin; Robert Elashoff; Philip J Clements; Michael D Roth; Daniel E Furst; Richard M Silver; Jonathan Goldin; Edgar Arriola; Charlie Strange; Marcy B Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fred Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky; Dinesh Khanna; Ning Li; Gang Li
Journal:  Am J Respir Crit Care Med       Date:  2007-08-23       Impact factor: 21.405

Review 9.  Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Authors:  Karen Au; Dinesh Khanna; Philip J Clements; Daniel E Furst; Donald P Tashkin
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

10.  Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study.

Authors:  Jonathan Goldin; Robert Elashoff; Hyun J Kim; Xaiohong Yan; David Lynch; Diane Strollo; Michael D Roth; Philip Clements; Daniel E Furst; Dinesh Khanna; Srainnapha Vasunilashorn; Gang Li; Donald P Tashkin
Journal:  Chest       Date:  2009-11       Impact factor: 9.410
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.